Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
An autocrine selected GLP-1R agonist was modified via site-specific fatty chain and exerted prolonged antidiabetic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1R agonists used in T2D treatment are either derivatives of native GLP-1 (liraglutide, albiglutide, semaglutide and dulaglutide), which have been modified to be resistant to DPP-IV inactivation or derivatives of exendin-4 (exenatide, lixisenatide and exenatide-LR).257,258”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [258]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2008) · Diabetes Care · doi:10.2337/dc08-1171 · Cited by 426
Roumie, C. L., Hung, A. M., Greevy, R. A., Grijalva, C. G., Liu, X., Murff, H. J., Elasy, T. A., & Griffin, M. R. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-9-201211060-00003 · Cited by 300
Markowicz-Piasecka, M., Sikora, J., Szydłowska, A., Skupień, A., Mikiciuk-Olasik, E., & Huttunen, K. M. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2199-y · Cited by 257
Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201
Plamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1847-7 · Cited by 173
Sarruf, D. A., Yu, F., Nguyen, H. T., Williams, D. L., Printz, R. L., Niswender, K. D., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-0899 · Cited by 151
Choi, S., Baudyš, M., & Kim, S. W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026435.27086.94 · Cited by 150
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P. A., Xie, J., He, L., Yea, K., Jones, T., Turn, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9918 · Cited by 137
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
GLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 113
Semaglutide: First Global Approval
Dhillon, S. (2018) · Drugs · doi:10.1007/s40265-018-0871-0 · Cited by 104
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94
Jimenez‐Solem, E., Rasmussen, M. H., Christensen, M., & Knop, F. K. (2010) · PubMed · Cited by 89
Hager, M. V., Johnson, L. M., Wootten, D. L., Sexton, P. M., & Gellman, S. H. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08323 · Cited by 85
Weissman, P., Goldstein, B. J., Rosenstock, J., Waterhouse, B., Cobitz, A. R., Wooddell, M. J., & Strow, L. J. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x74844 · Cited by 71
Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1
Hager, M. V., Clydesdale, L., Gellman, S. H., Sexton, P. M., & Wootten, D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.018 · Cited by 59
Novel approaches to drug discovery for the treatment of type 2 diabetes
Xu, X. Y., Wang, G., Zhou, T., Chen, L., Chen, J., & Shen, X. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.941352 · Cited by 52
Green, B. D., Gault, V. A., Mooney, M. H., Irwin, N., Harriott, P., Greer, B., Bailey, C. J., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.035 · Cited by 42
Zhang, Y., Ding, Y., Zhong, X., Guo, Q., Wang, H., Gao, J., Bai, T., Ren, L., Guo, Y., Jiao, X., et al. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.04.020 · Cited by 41
Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states
Farr, S., & Adeli, K. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834d68f0 · Cited by 40
Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
Leon, N., LaCoursiere, R. J., Yarosh, D., & Patel, R. S. (2017) · PubMed · Cited by 35
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
Penfornis, A., Borot, S., & Raccah, D. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73399-8 · Cited by 30
Redij, T., Chaudhari, R. R., Li, Z., Hua, X., & Li, Z. (2019) · ACS Omega · doi:10.1021/acsomega.8b03052 · Cited by 23
Bai, X., Niu, Y., Zhu, J., Yang, A.-Q., Wu, Y., & Ye, X. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.036 · Cited by 18
An automated liquid-chromatographic system for convenient determination of glycated hemoglobin A1c.
Saleh, A. K., & Moussa, M. A. A. (1985) · Clinical Chemistry · doi:10.1093/clinchem/31.11.1872 · Cited by 17
Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes
Wick, A., & Newlin, K. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00455.x · Cited by 13
Raee, M. R., Nargesi, A. A., Heidari, B., Mansournia, M. A., Larry, M., Rabizadeh, S., Zarifkar, M., Esteghamati, A., & Nakhjavani, M. (2017) · PubMed · Cited by 13
Cai, X., Sun, L., Dai, Y., Avraham, Y., Liu, C., Han, J. D. J., Liu, Y., Feng, D., Huang, W., & Qian, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.022 · Cited by 13
Li, C., Yang, M., Hou, G., Liu, S., Huan, Y., Yu, D., Sun, S., Liu, Q., Yan, S., & Shen, Z. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00169 · Cited by 6
Structure of human GLP-1(glucagon-like peptide-1) containing peptides
Ørskov, C., Kofod, H., Rabenhøj, L., Wettergren, A., & Holst, J. J. (1992) · Regulatory Peptides · doi:10.1016/0167-0115(92)90363-y · Cited by 5
Research works printed but not linked: 4
- Leon, 2017, P&T, 42, 676
- Raee, 2017, Arch. Iran. Med., 20, 141
- Blundell, 2016, Diabetes Res. Clin. Pract., 120, S119
- Jimenez-Solem, 2010, Curr. Opin. Mol. Ther., 12, 790
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Marzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121
The therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 98
Szunerits, S., Melinte, S., Barras, A., Pagneux, Q., Voronova, A., Abderrahmani, A., & Boukherroub, R. (2021) · Chemical Society Reviews · doi:10.1039/c9cs00886a · Cited by 49
Fang, Z., Chen, S., Manchanda, Y., Bitsi, S., Pickford, P., David, A., Shchepinova, M. M., Corrêa Jr, I. R., Hodson, D. J., Broichhagen, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218404 · Cited by 44
Metadata
- Authors
- Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y.
- Affiliations
- Sichuan University (CN)
- Hubei University for Nationalities (CN)
- China Pharmaceutical University (CN)
- Jiangnan University (CN)
- Corresponding author
- Yu, Yerong
- Venue
- RSC Advances
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2020
- Volume
- 10
- Issue
- 14
- Pages
- 8044-8053
- ISSN
- 2046-2069 (ISSN-L)
- PMC
- PMC9049875
- OpenAlex
- W3007502609
- Cited by
- 9
- References
- 33
- Citations by year
- 2023: 2 · 2021: 5 · 2020: 2
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- Open access
- gold
- doi.org
- Licence
- Locations
- RSC Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2012ZX10002006-003)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, G protein-biased agonists, semaglutide, type 2 diabetes, insulin resistance, glucose tolerance, beta-cell function, diet-induced obesity, dietary intake, weight management, inflammation, antidiabetic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.